Brighter has called upon a ninth Tranche of SEK 5 Million in line with the terms from the financing agreement communicated on the 26thof April 2017. The transaction is carried out through a private placement of convertible notes with warrants attached. It is the final tranche out of a commitment totaling SEK 100 million. It is precised that SEK 88.4 million of Notes of the previous Tranches out of the SEK 95 million have been converted into equity as of today, strengthening the company's balance sheet.
This investment as part of the agreement as such, serves as a great foundation regarding availability of financial resources for the company's continuous strategic and product development and enables Brighter to make further progress preparing for the sales and production of Actiste on national and international markets.
"With this last SEK 5 million tranche of the financing agreement with L1 Capital, completing SEK 100 million of convertible notes and associated Warrants to L1 Capital and Brighter's shareholders, totaling a potential additional SEK 107 million, we can establish that it has been a successful and cost-efficient capital acquisition solution for Brighter and its shareholders. The collaboration with L1 Capital has been the financing backbone for the final development and market introduction preparations for Brighter's Actiste Diabetes Management as a Service. We are particularly satisfied with the shareholder value created by the issuance of the Shareholder Warrants, minimizing dilution relative to the convertible notes and generating trading in the securities TO3 and TO4. The L1 Capital funds have been instrumental in positioning Brighter for the roll out of Actiste," says Truls Sjöstedt, CEO Brighter.
In connection with this transaction, Brighter will, similarly to the previous Tranches, also issue free warrants to existing shareholders, to protect them against dilution. The record date to receive one (1) free shareholder warrant (TO4) for every one hundred thirty seven (137) shares is January 9, 2019, which means that the last day of trading of shares including the right to receive TO4 is January 7, 2019. The first day of trading in the share excluding the right to TO4 will be January 8, 2019. The free shareholder warrants are of the same type as the investor's.
The terms and conditions of the Notes and the Warrants will also be published on Brighter's website.
Information about the financing agreement, including a follow-up table of the conversions, the number of Notes and the number of Warrants is also available under the following link: https://brighter.se/investors/financing.
For further information, please contact:
Truls Sjöstedt, CEO
Telefon: +46 709 73 46 00
Ann Zetterberg, CFO
Tel: +46 708 37 21 23
Brighter is a Swedish-based company that, from a unique IP portfolio, creates smart solutions for one of healthcare's biggest challenges: changing patient behavior. Chronic diseases such as diabetes are rapidly increasing, and account for an increasing share of healthcare costs globally. Brighter's Business Model and Multi-Sided Market Platform - The Benefit Loop®- is based on the fact that many special interests create value for each other. By increasing access to valid health data, Brighter creates value for all stakeholders in the care chain: patients and their close associates, healthcare providers, research institutes, the pharmaceutical industry, and society as a whole. www.brighter.se
The Company's shares are listed on NASDAQOMX First North/BRIG (http://www.nasdaqomxnordic.com/shares/microsite?Instrument=SSE86375). Brighter's Certified Adviser on Nasdaq OMX First North is Eminova Fondkommission AB, +46 (0)8 - 684 211 00, email@example.com, www.eminova.se.
This information is information that Brighter AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08:30 CET January 2, 2019.
This press release contains inside information as referred to in article 7 paragraph 1 of Regulation (EU) 596/2014 (Market Abuse Regulation).
With respect to Member States of the European Economic Area that have transposed European Directive 2003/71/EC of the European Parliament and European Council (as amended in particular by Directive 2010/73/EU to the extent that the said Directive has been transposed into each Member State of the European Economic Area), no action has been taken or will be taken to permit a public offering of the securities referred to in this press release requiring the publication of a prospectus in any Member State.
This press release and the information it contains do not, and will not, constitute an offer to subscribe for or sell, nor the solicitation of an offer to subscribe for or buy, securities of Brighter in the United States of America or any other jurisdiction. Securities may not be offered or sold in the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), it being specified that the securities of Brighter have not been and will not be registered within the US Securities Act. Brighter does not intend to register securities or conduct a public offering in the United States of America.
This information was distributed by Cision http://www.cisionwire.se/